Pharmacy-based Opportunistic Atrial Fibrillation Screening Integrated With Emergency Services (NUMAPLUS-FA)

Starting soon · Not applicable

Conditions studied: Atrial Fibrillation (Prevention of Stroke), Arrythmia, Cardiac, Mass Screening, Pharmacies

In brief

This study evaluates the feasibility and fidelity of an opportunistic atrial fibrillation (AF) screening programme conducted in 38 community pharmacies in Seville (Spain), using the Kardias® 6-lead portable ECG device, coordinated with the emergency medical services centre Salud Responde (CES 061) and primary care physicians. Eligible participants are individuals aged 65 years or older without a prior AF diagnosis who attend a participating pharmacy for any routine purpose. The screening consists of a 30-second ECG recording performed by a trained community pharmacist. Positive or indeterminate results are transmitted in real time to Salud Responde for clinical validation and referral to primary care. The study is evaluated using the RE-AIM framework (Reach, Effectiveness, Adoption, Implementation, Maintenance). The primary outcome is protocol fidelity, measured by the Implementation Adherence Grade (IAG). The study is part of the NUMAPLUS project, funded by INTERREG VI-A España-Portugal (POCTEP 2021-2027), co-financed by the European Regional Development Fund (ERDF).

Key facts

Study ID

NCT07598903

Run by

Centro de Emergencias Sanitarias 061 Andalucía

People needed

380

Starts

2026-06-01

Expected to finish

2026-12-31

Last updated by the study team

2026-05-22

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 65 years or older
• Attending a participating community pharmacy for any routine healthcare purpose
• No prior documented or patient-reported diagnosis of atrial fibrillation
• Capacity to provide written informed consent

You may not qualify if…

• Confirmed prior diagnosis of atrial fibrillation
• Implanted pacemaker, implantable cardioverter-defibrillator (ICD) or other intracardiac device
• Clinically evident haemodynamic instability requiring direct emergency 061 activation (active chest pain, severe dyspnoea, syncope)
• Concurrent participation in another cardiac rhythm monitoring study
• Inability to maintain the required position for a 30-second ECG recording

Where it is running

• Centro de Emergencias Sanitarias 061 — Seville, SEVILLA, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.